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Studies of the primary cilium, now known to be present in all
cells, have undergone a revolution, in part, because mutation
of many of its proteins causes a large number of diseases,
including cystic kidney disease. Bardet–Biedl syndrome (BBS)
is an inherited ciliopathy characterized, among other
dysfunctions, by renal defects for which the precise role of
the cilia in kidney function remains unclear. We studied a
cohort of patients with BBS where we found that these
patients had a urinary concentration defect even when
kidney function was near normal and in the absence of major
cyst formation. Subsequent in vitro analysis showed that
renal cells in which a BBS gene was knocked down were
unciliated, but did not exhibit cell cycle defects. As the
vasopressin receptor 2 is located in the primary cilium,
we studied BBS-derived unciliated renal epithelial cells and
found that they were unable to respond to luminal arginine
vasopressin treatment and activate their luminal aquaporin 2.
The ability to reabsorb water was restored by treating these
unciliated renal epithelial cells with forskolin, a receptor-
independent adenylate cyclase activator, showing that the
intracellular machinery for water absorption was present but
not activated. These findings suggest that the luminal
receptor located on the primary cilium may be important
for efficient transepithelial water absorption.
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The kidney is a target organ in many ciliopathies because of
its ciliated epithelium in which alteration of specific proteins
can lead to full-blown nephropathy with renal failure.1
Bardet–Biedl syndrome (BBS) is an emblematic ciliopathy in
which renal dysfunction occurs generally from late child-
hood, and is a major cause of morbidity and mortality.2,3 BBS
is because of mutations in at least 14 genes,1 causing defects
in the basal body/primary cilium complex.4 Previous studies
have described functional interactions between seven of the
BBS proteins, namely, BBS1, BBS2, BBS4, BBS5, BBS7, BBS8,
and BBS9, forming the BBSome, a protein complex required
for ciliogenesis,5 and very recently, a chaperon complex was
described in which the three chaperonin-like BBS proteins
BBS6, BBS10 and BBS12 were interacting to assist in the
formation of the BBSome.6
BBS has classically been defined by structural abnormal-
ities ranging from renal parenchymal cysts, communicating
calyceal cysts to dysplastic kidney, and horseshoe kidneys.7
Initial tubular dysfunction has also been described as well
as subsequent decreasing glomerular function leading to
chronic renal failure and renal transplantation,8 with a patho-
logy resembling another class of ciliopathy, the nephron-
ophthisis.9 Several mouse models have been generated and
intriguingly some mouse models developed renal cysts,10,11
whereas others did not,12,13 raising the question of cystogen-
esis factors for BBS.
Moreover, several groups have established that a frequent
initial renal dysfunction in the BBS patients is an impairment
of the urine concentrating ability causing polyuria and
polydypsyia, and that this defect was the result of decrease
responsiveness to the antidiuretic hormone vasopressin
(AVP).2,9,14–16 Water reabsorption in the collecting ducts is
tightly regulated by AVP,17 which binds to its V2 receptor
(AVPR2) and triggers cyclic adenosine monophosphate
(cAMP)/protein kinase A (PKA)-mediated phosphorylation
of the aquaporin 2 (AQP2),18 leading to a redistribution of
intracellular vesicles to the apical membrane, whereas the
other isoform of the AVP receptor AV1aR’s function is to
antagonize the water absorption activation mediated by
AVPR2.19 Hitherto, the AVPR2 receptor, was described to be
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localized on both the basolateral and the apical membrane of
the renal cell of the distal nephron20 but recently, AVPR2
ciliary localization was evidenced to be associated with the
required machinery to increase intracellular cAMP because of
the presence of an adenyl cyclase enzyme.21 Interestingly,
there is a substantial amount of urinary AVP with a
concentration ranging between 5 and 500 picomol/l asso-
ciated with a urinary clearance of 0.1–0.6ml/kg/min.22 It is
therefore conceivable that the ciliary AVPR2 is able to detect
the luminal AVP and to trigger water reabsorption, a
hypothesis that has, so far, remained unaddressed.
To verify these different hypotheses, we used a combina-
tion of clinical investigations and in vitro analysis. A total of
33 BBS patients were tested for their renal anatomical
characteristics and functions. Most of the patients showed
maintained renal function with no major cystogenesis, with
urinary concentration defect after fluid deprivation as the
most frequent phenotype. Using these clinical data as starting
point, we performed a series of in vitro tests focusing on
the chaperonin-like BBS proteins, as our clinical data show
more overt kidney dysfunction in patients with mutations in
BBS chaperonin-like proteins.23 Upon BBS inactivation, the
primary cilium carrying the AVPR2 was lost, rendering the
renal epithelial cell insensitive to luminal AVP treatment.
These unciliated BBS-deprived cells were unable to activate
their AQP2 explaining why the unciliated cells could not
absorb water. Interestingly, the water reabsorption process
was pharmacologically restored by increasing intracellular
cAMP. These findings suggest that water reabsorption in the
collecting duct is mediated by the primary cilium.
RESULTS
Human renal BBS phenotype
To determine how the BBS protein inactivation impairs renal
function, we investigated the renal phenotype in 33 (neither
dialysed nor transplanted) BBS patients (for age, sex, and
genotype; see Supplementary Table S1 online). Most patients
had normal mean kidney size (Figure 1a and b), with rare cases
of moderate cortical cystogenesis; even in the case where the
patient had a massive cyst (Figure 1b). The most prominent
urinary phenotype observed in these BBS patients was a
urinary concentration defect (Figure 1c), as their urinary
osmolalities remained below 750mOsmol/kg of water after a
12-h fluid deprivation. To show that this urinary concentra-
tion defect was not the consequence of renal failure, we
correlated the urinary osmolalities and the measured 24-h
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Figure 1 |Human BBS renal phenotype. MRI imaging analysis of a cohort of 17 BBS patients showed normal renal dimensions (a) of
115±12 by 47±9mm (b) even for the case of one patient showing a large cyst. (c) Percentages of tested patients with the indicated
measured renal parameters (x axis). (d) Dot plot showing the relationship between the urinary osmolality after 12-h fluid deprivation in BBS
patients and control individuals versus the measured 24-h creatinine clearance. The horizontal dot line corresponds to the urinary osmolality
threshold (750mOsmol/kg H2O) under which a urinary concentration defect was established. For the creatinine clearance, the lower
threshold was set ato60ml/min under which the patients were considered suffering from frank renal failure, and the upper threshold was
set at 4170ml/min. BBS, Bardet–Biedl syndrome.
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creatinine clearance for both BBS patients and a control group
of healthy individuals matched with age (for age and sex; see
Supplementary Table S2 online) under the same conditions
of fluid deprivation as the BBS patients (Figure 1d). We
excluded from the analysis patients in frank renal failure with
a measured creatinine clearance inferior to 60ml/min as well
as patients with a measured creatinine clearance superior to
170ml/min because of a major hyperfiltration status
associated with severe obesity (body mass index440; data
not shown) as described previously.24–26 In all, 63% of the
BBS patients in this range of renal function (60–170ml/min)
could not concentrate their urine adequately after fluid
deprivation (Figure 1d), whereas 100% of the healthy
controls concentrated their urine properly, with a urinary
osmolality above 750mOsmol/kg of water.
Cellular localization of BBS proteins in renal epithelial cells
We studied two regions of the nephron, namely, the proximal
tubule by use of the human primary renal proximal tubule
epithelial cells and its corresponding cell line HK-2, as well
as the collecting duct segment by use of a human collecting duct
(HCD) cell line. We focused on the members of the vertebrate-
specific chaperonin-like BBS group,27–29 namely, BBS6, BBS10,
and BBS12, and found that all three proteins retained centriolar
localization at the cytodieric bridge between two dividing cells
(Figure 2a), at full confluence (Figure 2b), and in the basal body
of ciliated cells (Figure 2c); even in the absence of intact micro-
tubules (Supplementary Figure S1 online). Immunostaining
for the acetylated a-tubulin on an adult human kidney section
showed the primary cilia in the luminal area (Figure 2d).
Absence of BBS proteins does not impair cell cycle
As it was reported that BBS-deprived cells suffered from
cell cycle defects,29 we checked whether BBS6 or BBS10 or
BBS12 inactivation could impact the cell cycle progression.
Knockdown of each of the three BBS proteins was achieved
(Figure 3a) in the proliferating renal HK-2 and HCD cells,
and did not impair cell cycle progression (Figure 3b and c).
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Figure 2 |Cellular localization of the chaperonin-like BBS proteins. (a) Indicated BBS proteins were detected at the cytodieric
bridge in dividing hRPTECs. (b) Colocalization of BBS proteins with the centrioles (g-TUB) in confluent hRPTECs. (c) BBS proteins were
detected at the base of the primary cilium (a-TUB) in differentiated ciliated hRPTECs. All scale bars are 5 mmol/l. (d) Representative picture
showing primary cilia of the epithelial cell in a healthy adult human kidney section. BBS, Bardet–Biedl syndrome; hRPTECs, human renal
proximal tubular epithelial cells; TUB, tubulin.
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We could show that the inactivation of either BBS10 or
BBS12 was not associated with an adaptive response of the
interacting BBS proteins, as the expression levels of either
BBS6 and BBS12 or BBS6 and BBS10, respectively, remained
unchanged (Figure 3d). Confirming these findings, BBS10
and BBS12 patients’ dermal fibroblasts expressing either a
mutated form of BBS10 or no BBS12 protein, respectively,
(Figure 3e) also did not show any cell cycle defect (Figure 3f
and g). These studies demonstrate that chaperonin-like
BBS inactivation does not interfere, in vitro, with the
cell cycle progression in human renal epithelial cells.
This finding could explain why no BBS patient tested
in this study presented increased kidney size or major
cystogenesis.
Luminal AVP is detected by ciliary AVPR2
As the most frequent BBS-associated renal dysfunction is a
urinary concentration defect and that vasopressin-resistant
status has been suggested for BBS, we investigated what could
be the link between the BBS-induced ciliary defect and water
reabsorption. The collecting duct is the site where water
absorption is regulated by AVP; we therefore verified the
localization of the AVPR2 with the primary cilium on adult
human kidney sections (Supplementary Figure S2 online for
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Figure 3 | Inactivation of the BBS proteins does not impair cell cycle progression. The 40% confluent HK-2 cells were transfected with
either BBS6 or BBS10 or BBS12 or negative RNAi control. (a) Immunodetection after 48 h of transfection of the indicated proteins showed
drastic drop in protein content after RNAi treatment (lane 1: control RNAi, lanes 2 and 3: cognate BBS RNAi duplex). (b) Representative
pictures after staining for b-tubulin and DAPI following different control- or BBS10-RNAi. The 53 RNAi-transfected cells served as positive
control for cellular abnormalities (right picture). (c) Fluorescent-activated cell sorting analysis for the cell cycle profile after 48 h of RNAi
treatment showed absence of cellular abnormalities except for p53-deficient cells (n¼ 3). (d) After 48 h of transfection with small interfering
RNA against either BBS10 or BBS12 in HK-2 cells, RNA was extracted and used for quantitative real-time PCR. The relative expression levels of
each of the three interacting BBS–chaperonin-like BBS mRNA (BBS6, BBS10, and BBS12) compared with the 18S rRNA as reference (P-
valueo0.05; n¼ 3). Primer sequences are depicted in Supplementary Table S3 online. (e) Dermal biopsy-derived fibroblasts from a healthy
control, a BBS10, and a BBS12 patient were analyzed, and showed BBS10 expression in the BBS10-mutated fibroblasts and total absence of
BBS12 protein in the BBS12-mutated fibroblasts. No cell cycle defect was detected (f, g; n¼ 3). All scale bars are 10 mmol/l. BBS, Bardet–Biedl
syndrome; Cont., control; DAPI, 40,6-diamino-2-phenylindole; Mr, molecular weight; Pat., patient; RNAi, RNA interference.
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antibody characterization). AVPR2 was concentrated in the
medullary region (Figure 4a, b and Supplementary Figure S3
online) and, at higher magnifications, was observed on the
human primary cilia (Figure 4c). For our subsequent in vitro
analysis, HCD cells were subsequently used, as they originate
from the AVP-sensitive epithelial renal cells. These cells
undergo ciliogenesis at full confluence, and immunostaining
for AQP3 and acetylated a-tubulin for the primary cilium
was carried out to demonstrate that the HCD cells retained
normal physiological apical–basolateral polarization (Figure
4d). The HCD’s primary cilium also carried the AVPR2
receptor (Figure 4e), similarly to what was described in the
MDCK renal cells.30 AVP binding to the AVPR2 receptor
triggers an increase in intracellular cAMP, leading to the
induction of PKA-mediated phosphorylation of AQP2 and to
its apical membrane targeting.31 cAMP measurements in the
epithelial cells following incubation with different concentra-
tions of luminal AVP (Figure 4f) highlighted that HCD cells
were able to detect relatively low amount of luminal AVP.
Apical AVP treatment induced the phosphorylation of AQP2
(Figure 4g; see Supplementary Figure S4 online for loading
controls), which was dramatically reduced in the presence
of the most potent antidiuretic AVP antagonist, d(CH2)5
1,D-
Phe2,Ile,Ala-NH2
9)-vasopressin. As the phosphorylated AQP2
was detected at 60 kDa, we carried specific short hairpin
RNA-mediated knockdown of AQP2 in the HCD cells that
resulted in a clear reduction of the 60 kDa band, indicating
that this band did correspond to the phosphorylated AQP2
(Supplementary Figure S5 online). The phosphorylated AQP2
was targeted toward the apical side (Figure 4h), and three-
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Figure 4 |Ciliary AVPR2 is able to activate aquaporin 2 (AQP2) targeting in vitro. (a, b) Immunofluorescence imaging of the medullary
region on adult human kidney showing antidiuretic hormone vasopressin receptor 2 (AVPR2; green) and the stable acetylated form of
a-tubulin (red). Staining of AVPR2 is specific as denoted by specific staining in the arteriole wall, which remains green on the merged picture
(Supplementary Figure S2 online). (c) At higher magnification, AVPR2 was detected on the primary cilium. (d) Three-dimensional (3D) imaging
performed after immunodetection of AQP3 (basolateral side; green) and the primary cilium (apical side; red) indicating that the human
collecting duct (HCD) cells retained their physiological polarization in culture. (e) HCD primary cilium (green) carries the AVPR2 receptor
(red). (f) Quantification of intracellular cyclic adenosine monophosphate (cAMP) after 90 s of luminal AVP treatment on control (CTRL;
wild-type) WT cells with different concentrations of AVP (*P-valueo0.05; n¼ 4). (g) Immunodetection of phosphorylated AQP2 (p-AQP2) in
triplicates after luminal 108mol/l AVP treatment with or without the most potent AVP antagonist (d(CH2)5
1,D-Phe2,Ile,Ala-NH2
9)-vasopressin).
(h) The 3D imaging of the nuclei, AQP3, and AQP2 after luminal AVP treatment. (i) In-cell 3D imaging depicting that AQP2 is on the apical
side and AQP3 on the basolateral side. (j) Immunodetection of p-AQP2 after basolateral AVP treatment in triplicates on control WT HCD
cells. Antag., AVP antagonist; Unt., untreated cells.
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dimensional (3D) modelization of the HCD cell after luminal
AVP treatment showed clear separation between the apical
AQP2 and the basolateral AQP3 layers (Figure 4i). The HCD
cells also retained their physiological basolateral localization
of the AVPR2 receptor, as AVP basolateral treatment also
induced the phosphorylation of AQP2 (Figure 4j).
BBS-deprived renal epithelial cells are unciliated
We generated a constitutively deprived BBS10 HCD (BBS10-
HCD) cell line with no BBS10 protein expression (Figure 5a).
No significant difference in expression levels of either AQP2
or APQ3 was found, whereas an increase in AVPR2
expression was observed (Figure 5a). No difference was
detected in cellular growth rates between BBS10-HCD cells
and control HCD cells (Figure 5b). Cell volume distributions
are intrinsic characteristic of cell population and whenever
cellular stress occurs, there are variations in these distribu-
tions.32,33 We determined the cell volume distributions of
both the BBS10-HCD cells and the control HCD cells, and
found no difference between these cells (Figure 5c).
Interestingly, when HCD cells reached full confluence,
ciliated cells were observed in control cells (Figure 5d),
whereas the BBS10-HCD cells remained unciliated (Figure 5e).
Knockdown of the other chaperonin-like BBS also resulted
in primary cilium loss (Supplementary Figure S6 online).
To determine the effect of the primary cilium loss on
the AVPR2 ciliary targeting, we generated AVPR2-green
fluorescent protein (GFP)-expressing ciliated cells (shCTRL-
HCD) and non-ciliated cells (shBBS10-HCD), and per-
formed live-cell imaging. A focal point was detected with the
Image-iT (arrows, Invitrogen) in ciliated cells corresponding
to the localization of the primary cilium (shCTRL-HCD)
(Figure 5f) and coinciding with localization of the AVPR2-
GFP. By contrast, diffused staining was obtained with the
Image-iT depicting the absence of primary cilium (shBBS10-
HCD) with a similar diffused expression pattern for the
AVPR2-GFP (Figure 5g). These results indicate that, in
absence of primary cilium, the AVPR2 ciliary targeting is
abrogated.
Unciliated renal epithelial cells are unable to detect luminal
AVP and to target AQP2 to their plasma membrane
To verify whether unciliated cells could still detect the
luminal AVP and induce a cAMP intracellular increase,
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Figure 5 |Ciliary antidiuretic hormone vasopressin receptor 2 (AVPR2) targeting is lost after Bardet–Biedl syndrome 10 (BBS10)
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we cultured BBS10-, BBS6-, and BBS12-deprived HCD
cells (Figure 6a). Upon luminal AVP treatment, intracellular
cAMP was measured in either control HCD cells or BBS6- or
BBS10- or BBS12-deprived HCD cells (Figure 6b) that
showed significant cAMP increase in control cells and no
increase in BBS-deprived HCD cells. As expected, AQP2-P
was readily detected in control ciliated HCD cells (Figure
6c–e; lanes 1) but remained absent in unciliated cells (Figure
6c–e, lanes 2–3), without significantly impacting the AQP3
protein expression levels. Interestingly, these unciliated cells
maintained their ability to detect basolateral AVP as depicted
by a clear increase in AQP2-P after AVP basolateral treatment
(Supplementary Figure S7 online). Without AVP treatment,
AQP2 was detected in a diffused manner with the AQP3
mostly concentrated on the basolateral side (Figure 6f). After
luminal AVP treatment of the control ciliated HCD cells,
the cAMP-induced phosphorylation of AQP2 resulted in its
membrane translocation (Figure 6g); an effect that did
not occur in unciliated BBS10-HCD cells (Figure 6h).
Similar lack of AQP2 targeting was observed in transiently
BBS6- and BBS12-inactivated HCD cells (Supplementary
Figure S8 online).
Water re-absorption is restored by forskolin (FOR) treatment
Our findings show that the apical AVPR2 possesses the exact
same activating capacity on the AQP2 as the basolateral one,
but raises the question of the water reabsorption function.
We first checked whether HCD cells were capable of
aquaporin-mediated water absorption. Water transport was
determined by measuring the apical and basolateral medium
volumes using a precision balance after 2 h incubation in the
presence of an osmotic gradient with or without luminal AVP
and in the presence or absence of mercury chloride, an
aquaporin inhibitor. No volume change was measured in
both compartments in absence of AVP (Figure 7a), whereas
upon addition of luminal AVP, a significant decrease in apical
AQP3
CT
RL
-H
CD
-A
VP
CT
RL
-H
CD
+A
VP
BB
S1
0-
HC
D+
AV
P
AQP3
AQP3
AQP2
AQP2
AQP2
Merged
Merged
Merged
f
g
h
BBS6
BBS12
60
Mr (kDa)321
79
a
2.5
2
1.5
1
0.5
cAMP†
* *
*
cA
M
P/
to
ta
l p
ro
te
in
(×1
0 
μm
o
l/μ
g)
0
CTRL
–
10–8mol/l AVP
CTRL
+
BBS6
+
BSS10
+
BBS12
+
b
1 2 Mr (kDa)
60
36
AQP2-P
AQP3
shBBS10+ AVPc
1 2 3 Mr (kDa)
60
36
AQP2-P
AQP3
shBBS12+ AVPd
1 2 3 Mr (kDa)
60
36
AQP2-P
AQP3
shBBS6+ AVPe
Figure 6 | Loss of cilia inhibits cyclic AMP (cAMP)-induced aquaporin 2 (AQP2) targeting to the plasma membrane. (a) Western blots
indicating that 48 h RNA interference treatment resulted in efficient knockdown of cognate proteins (Bardet–Biedl syndrome (BBS)12 and
BBS6). (b) Quantification of intracellular cAMP after 90 s antidiuretic hormone vasopressin receptor (AVP) treatment in BBS-lacking HCD
(human collecting duct cell line) cells (w,*P-value o0.001; n¼ 4) showing lack of cAMP production after luminal AVP treatment, which was
directly correlated with the absence of phosphorylation of AQP2 (AQP2-P) without any effect on AQP3 levels (c–e) (lanes 1: control lysates,
lanes 2 and 3: BBS-deprived cell lysates; loading controls, Supplementary Figure S4 online). (f–h) 3D modelization after immunodetection of
both AQP2 and AQP3. (f) In the absence of AVP, AQP2 remained diffused in the perinuclear region of the cell. Following 30-min luminal
108mol/l AVP treatment on ciliated HCD cells, AQP2 was concentrated in the apical region of the cells (g), which did not occur in the
absence of BBS10 protein (h). Blue staining represents the nuclei.
Kidney International (2011) 79, 1013–1025 1019
V Marion et al.: Primary cilium and renal water absorption o r ig ina l a r t i c l e
volume was measured accompanied by a significant increase
in basolateral medium, indicating water movement from the
apical to the basolateral region. When mercury chloride was
added to both compartments, water movement was sig-
nificantly reduced. Once we were able to validate the presence
of an active AVP-induced water transport in HCD cells, we
used the dye dilution experimental approach (schematized in
Supplementary Figure S9a and b online), which indirectly
measured water movements across the cells. Upon luminal
AVP treatment, water movement from the luminal side to the
basolateral side leads to an increase in the apical fluorescence
levels. The advantage of this technique compared with the
measurement of medium volumes lies in its increased
precision, allowing us to measure smaller changes in
fluorescence that is directly correlated to smaller volume
changes. Fluorescence levels remained unchanged in the
apical compartment in untreated ciliated control cells
(CTRL-AVP) in absence of AVP treatment (Figure 7b),
whereas a significant rise in fluorescence levels, indicating
water movement, was detected when luminal AVP was given
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Figure 7 |Water re-absorption is re-activated upon restored cyclic AMP (cAMP) signaling. (a) Measurement of medium weight
with the indicated treatment in wild-type human collecting duct (HCD) cells showing that the aquaporin inhibitor, mercury chloride,
inhibited water movement (w,*Po0.05; n¼ 4). (b) Control and BBS10-deprived HCD cells were incubated on the luminal side with
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on the luminal side of control ciliated cells (CTRLþAVP;
Figure 7b). Fluorescence levels remained constant in AVP-
treated BBS cells, demonstrating that unciliated cells were
unable to absorb water after luminal AVP treatment
(BBS10þAVP; Figure 7b).
We then verified whether the absence of water absorption
was because of a ciliary-induced defect in the luminal AVP
detection or whether it was the result of a complete in-cell
deficiency of the water absorption machinery. Both ciliated
and unciliated HCD cells were treated with the receptor-
independent adenylate cyclase activator FOR, causing a
significant increase in intracellular cAMP compared with
untreated cells (Figure 7c). As FOR may have multiple
cellular effects, we verified the expression levels of AQP2 and
AQP3, as well as the phosphorylation status of AQP2 (Figure
7d). No significant difference in expression levels of AQP2
and AQP3 was detected after FOR treatment, whereas a clear
phosphorylation of AQP2 was observed in both control and
BBS10-deprived HCD cells. Interestingly, AQP2, which
remained diffused in unciliated cells after sole luminal AVP
treatment (Figure 7e), was highly concentrated on the apical
side of the unciliated HCD cell upon FOR treatment (Figure
7f), showing that unciliated cells are still able to target their
AQP2 to the plasma membrane. The 3D modelization of the
FOR-treated unciliated HCD cells demonstrated restored
AQP2 apical targeting (Figure 7g). Concomitant to this
restituted targeting of AQP2, an identical increase in
fluorescence levels was measured in both ciliated and
unciliated cells, indicating reestablishment of water absorp-
tion (Figure 7h).
DISCUSSION
BBS renal pathogenesis remains to be elucidated in the
context of cilia dysfunction, thus a series of tests to try to
elucidate the exact renal pathology occurring during BBS was
carried out. Kidney disease in ciliopathies is usually
monitored by imaging of the kidney that allows the detection
of multiple cysts with or without kidney enlargement1 in
PKD or nephronophthisis, respectively.34 We found 23% of
the patients with minor cystogenesis without increase in
kidney size, even for one patient (Figure 1b) presenting a
large cyst formation. As the inactivation of certain BBS
proteins could impair cell cycle progression,29 we verified
whether the lack of chaperonin-like BBS proteins could
interfere with the cell cycle. Such defect could not be
observed in BBS-deprived renal cells, a finding confirmed by
studies on dermal fibroblasts derived from BBS patients. In
view of these results, BBS does not fit in the category of
classical cystogenic kidney disease. Intriguingly, renal
abnormalities associated with major cystogenesis in previous
studies were detected ranging from 50 to 72% of the tested
patients.7,35,36 A possible reason explaining the difference in
occurrence of cystogenesis could be because of the age
difference, as the patients included in our study were younger
than those previously studied. To address this issue, we
have another clinical research protocol underway where
the same patients are being tested for the presence of
cysts. These new set of data should allow us to verify whether
the occurrence of characteristic cystogenesis is age dependent
in BBS.
It has already been described2,9,14–16 that the most frequent
renal dysfunction in BBS patients was a urinary concentra-
tion defect. Interestingly, our clinical data put in evidence
that this urinary concentration defect in BBS is detected,
although the patients have preserved renal function as
indicated by their creatinine clearance measurements.
With the recent finding that the primary cilium was carrying
the AVPR2 receptor,30 this prompted us to verify whether
the BBS-induced ciliary defect could be responsible for the
patients’ most prominent initial phenotype. In vitro BBS
proteins’ inactivation was responsible for the primary cilium
loss inhibiting efficient luminal AVP detection. This effect
was responsible for the lack of AQP2 activation, causing an
absence of water absorption. These data suggest that the BBS
patients are unable to concentrate maximally their urine after
fluid restriction, as they cannot detect efficiently their urinary
luminal AVP.
Antidiuresis impairments are not solely found in BBS, as it
also happens in the dominant polycystic kidney disease37
caused by mutations in the PKD gene coding for a ciliary
protein. Indeed, in the heterozygous Pkd1þ / mice, the
authors showed that the mice were suffering from high urine
osmolality despite normal renal function and water intake.
The comparison between the BBS and the PKD murine
phenotype is intriguing, as in both cases, normal renal
function and normal water intake were maintained, with one
major difference, the opposite effect on urine osmolality. In
these heterozygous Pkd mice, the whole AVP signaling
cascade was overactivated as shown by higher levels of both
AQP2 and RhoA phosphorylation, indicating that these renal
cells were able to perfectly detect extracellular AVP. This
positive water balance observed in the heterozygous Pkd
mice is probably because of the excessive expression of AVP
in the brain as discussed by the authors.37 In BBS-deprived
cells, the cells cannot detect the luminal AVP and therefore
cannot activate the PKA-mediated phosphorylation of
both AQP2 and RhoA. In BBS-deprived renal cells,
AQP2 gets phosphorylated when PKA activation is restored
by FOR as is RhoA (data not shown). These data implies that
in BBS, the in-cell machinery at least for the activation of the
downstream targets of PKA is intact. To verify a possible
implication of cerebral impairment in the renal dysfunction
observed in BBS, further investigations are required.
Our data might seem in contradiction to what is generally
thought of the mechanism of action of AVP after fluid
restriction. Indeed, plasma vasopressin is widely thought to
bind to the AVPR2 receptor localized at the basolateral
membrane, which in turn regulates AQP2 insertion into the
apical membrane. Although this is a commonly accepted
signaling mechanism of AVP in the kidney and is most
certainly having a role in water reabsorption in the collecting
duct, we would like to hypothesize that the first wave of AVP
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detected by the renal epithelial cell is not on its basolateral
plasmatic side but more on its urinary luminal side, and is
detected by the primary cilium carrying the AVPR2. The
finding supporting this hypothesis is based on a previously
published data where AVP was infused in healthy human
subjects and where plasma AVP was observed to be only
slightly increased to reach a plateau, whereas the urinary AVP
concentration was increasing at a rate of 120 times more
rapidly than that of plasma and was increasing linearly with
increasing infusion rates of AVP.38 This means that AVP
cerebral release is primarily reflected by a rapid urinary
AVP increase probably detected by the primary cilium
and by a later, more subtle increase in basolateral AVP
concentration.
Nonoguchi et al.20 described that the effects of luminal
vasopressin in the inner medullary collecting duct opposed
those of basolateral vasopressin and reduced water perme-
ability. Interestingly, these effects were detected only after
basolateral AVP treatment. On the other hand, when they
first treated the epithelial cell with AVP on the luminal side,
they found an increase in water permeability. This means that
depending on which side of the epithelial cell is treated first,
the luminal AVP has either activating or inhibitory effects on
water reabsoprtion.
In the absence of AVP, AVPR2 activating AQP2 was found
on the primary cilium as depicted in immunostainings on
human kidney sections, which was reproduced in vitro in the
HCD cells. On the other hand, the isoform AV1aR, whose
action is to antagonize the AVPR2 action on water
absorption, was detected in a diffuse manner throughout
the HCD cells and not in the primary cilium, in absence of
AVP (Supplementary Figure S9c online). Interestingly, Breyer
et al.39 showed that vasopressin has effects in the lumen of the
cortical collecting duct that were mediated through V1aR
receptor after treatment with basolateral AVP. Based on
these data, we would like to suggest a signaling cascade
taking place in the renal epithelial cell of the collecting duct,
with the primary cilium having a central role: in absence of
AVP, AVPR2 is localized on both the basolateral side and on
the primary cilium of the apical side for more efficient
detection of AVP in the urine. Upon fluid restriction, AVP is
released and is first detected by the primary cilium, and also
by the basolateral side that triggers water reabsorption
mechanism. Concomitant to the intracellular increase in
cAMP and AQP2 membrane targeting, the AVPR2 receptor
is recycled, whereas the AV1aR is targeted to both
the basolateral and apical membranes to control water
reabsorption.
These findings, although supported by clinical data, will
need to be verified in more physiological in vivo studies with
the proper mouse models and more thorough clinical
investigations. This is why a new clinical research protocol
is currently underway combined with the study of a
conditional knockout mouse for the Bbs10 gene that will be
used to fully verify the proposed signaling cascade. Overall,
the data presented in this study highlight the fact that urinary
AVP is having a crucial role in the antidiuresis process, with
the primary cilium allowing its efficient detection. Under-
standably, primary cilia dysfunction leads classically to initial
deficient urine concentration in well-recognized ciliopathies,
such as for nephronophthisis and BBS. However, in contrast
with nephrogenic insipidus diabetes (because of mutations in
the arginine vasopressin receptor gene), end-stage renal
disease in ciliopathies may occur early on, suggesting that
further pathways leading to kidney failure remain to be
dissected.
MATERIALS and METHODS
BBS cohort and clinical analysis
The cohort includes 33 patients who were diagnosed BBS based on
the association of at least 3 of the cardinal features of the syndrome,
that is, retinitis pigmentosa, polydactyly, obesity, cognitive impair-
ment, renal dysfunction, and/or combined with mutations in the
known BBS genes7 (Supplementary Table S1 online). Exclusion
criteria were age o16 years, pregnancy, or interfering illness. No
patient had renal dialysis or renal transplantation. Patients provided
written informed consent under the authority of the local ethics
committee. Abdomino–pelvic MRI was performed, if the degree of
obesity authorized the entry in the MRI setting (n¼ 17). Urine
measurements were performed over 24 h for protein and albumin
levels. Fresh urine was analyzed for pH determination; hematuria
and microscopic analysis was done for signs of infections. Renal
function was estimated with 24 h creatinine clearance. A 12 h fluid
deprivation was initiated in the evening, and 12 h later by early
morning, urinary osmolality was determined. A control group of
11 healthy subjects matched for age (22–39 years old) (see Supple-
mentary Table S2 online) was tested to establish the threshold for
normal urinary concentration response after 12 h water deprivation.
Abnormal urine concentration ability was diagnosed when the osmolality
was o750mOsmol/kg H2O.
Cell culture and conditions
Primary human renal proximal tubular epithelial cells (catalog #
CC-2553; Lonza, Verviers, Belgium) were cultured in renal epithelial
growth medium (catalog #: CC-3190; Lonza). Proximal tubular
epithelial cell line HK-2 (ATCC #: CRL-2190, Molsheim, France)
was cultured in Dulbecco’s modied Eagle’s medium containing
insulin/transferrin/selenium (catalog #: 41400-045; GIBCO,
ThermoFisher, Paris, France), 2% fetal bovine serum, and
penicillin/streptomycin (catalog #: 15240; GIBCO) at 371C humi-
dified 5% CO2. hRPTEC and HK-2 cells were grown to full
confluence and left to differentiate for 8 days, resulting in
ciliogenesis. HCD40 was cultured in Dulbecco’s modied Eagle’s
medium–HAM’s F12, Glutamax (Invitrogen, ThermoFisher, Paris,
France), insulin/transferrin/selenium, 2mmol/l dexamethasone, and
2% fetal bovine serum. For selective apical or basolateral treatment,
HCD cells were grown on Millicell Cell Culture Insert (catalog #:
PIRP30R48, Millipore, Molsheim, France) in six-well plate. Culture
medium without dexamethasone containing AVP (Sigma-Aldrich,
catalog #: V0377; Lyon, France) was added in the Millicell insert on
either the apical or the basolateral side of the HCD cells. After
incubation, the cells were analyzed on western blot after trichlor-
oacetic acid precipitation. Dermal fibroblasts were cultured in
Dulbecco’s modied Eagle’s medium, Glutamax, 10% fetal bovine
serum, and penicillin/streptomycin.
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Western blots and immunofluorescence microscopy
Cellular proteins were obtained by trichloroacetic acid precipitation.
Antibody binding was visualized using Western Blot Kit (catalog #:
96-9045, Invitrogen). For immunofluorescence experiments, the
cells were seeded on permanox 8-wells Lab-Tek II Chamber Slide
(catalog #: 177445; NUNC, ThermoFisher). Cells were treated as
indicated and were finally processed for protein detection after
methanol fixation and permeabilized with 0.1% Triton X-100. The
microscopy slides were mounted for detection with Vectashield
Mounting Medium with 40,6-diamino-2-phenylindole (catalog #: H-
1200; Vector Laboratories, Abcyss, Paris, France). To view mem-
brane-associated proteins, cells were formalin fixated for 15min and
directly blocked, followed by immunostaining and acquisition. After
informed written consent from the adult patient and under strict
regulation of the local ethical committee, the kidney biopsy was
fixated overnight at 41C in 4% formaldehyde phosphate buffered
(40mmol/l. pH 7.0–7.4) (J.T. Baker, Deventer, The Netherlands).
The tissue was washed with running tap water for 30min, and was
dehydrated with increasing series of ethanol for 4 h each with
constant agitation. For complete dehydration, the sample was
incubated in Ultraclear (J.T. Baker) two times for 2 h each before
paraffin infiltration (Paraclean, Klinipath, The Netherlands), which
was performed at 601C under vacuum. The sample was then
embedded in a paraffin block, and 7mm-thick sections were made
with a Leica RM 2245 microtome (Leica Microsystems, Rijswijk, The
Netherlands) and mounted on Superfrost Plus microscope slides
(ThermoScientific, Braunschweig, Germany) for analysis. After
deparaffination and hydration, the sections were stained and analyzed.
RNA extraction and quantitative PCR
Total RNA was extracted with Trizol (catalog #: 15596-018, Invitrogen).
Total RNA of 1 mg was reverse transcribed using the iScript comple-
mentary DNA synthesis kit (catalog #: 170-8891, Biorad, Marne-la-
coquette, France). Primer sequences (Supplementary Table S3
online) were optimized for an annealing temperature of 601C.
Complementary DNA samples for messenger RNA determination
was diluted 30-fold before use and those of 18S ribosomal RNA 60-
fold. Primary fluorescent data were exported and analyzed with the
Lin-Reg Analysis program.41 Messenger RNA concentrations were
expressed as relative to 18S ribosomal RNA content.
Animal husbandry
Wild-type animals were on a C57/B6 background. Mice were housed
in humidity- and temperature-controlled rooms on a 12-h light/
12-h dark cycle with food and water ad libitum. Animals were killed
by decapitation and after dissection, the kidneys were snapped
frozen in optimal cutting temperature compound (Tissue-Tek,
Zoeterwoude, The Netherlands) using liquid nitrogen.
Antibodies
Primary antibodies used: rabbit polyclonal anti-BBS10, mouse
monoclonal anti-BBS6 (clone number 1E4), and rabbit polyclonal
BBS12 antibody were obtained from the IGBMC (Strasbourg, France);
mouse monoclonal anti-b-tubulin (catalog #: TUB-2A2, EUROME-
DEX, Souffeiw., France), rabbit polyclonal antibody anti-AVPR2-V2
(catalog #: AB1797) from Millipore; rabbit polyclonal anti-AQP2 and
goat polyclonal anti-aquaporin 3 (catalog #: sc-28629 and sc-9885,
respectively) from Santa Cruz Biotechnology (Tebu Bio, Yvelines,
France); mouse monoclonal anti-g-tubulin, rabbit polyclonal anti-
AQP2 phospho-S261, and rabbit anti-arginine vasopressin receptor
(AVPR-V2) (catalog #: ab11316-100, ab72383 and ab179P, respectively,
Abcam, Paris, France). As the phosphorylated form of the AQP2 was
higher than the expected size, we tested two other antibodies, namely,
the rabbit polyclonal antibodies anti-phosphor-AQP2 S261 from
Abnova and ABSerotec (Colmar, France), respectively, (catalog #:
PAB9646 and AHP1299), which detected the same band at 60 kDa (see
Supplementary Figure S5 online for characterization of the band at
60 kDa). The mouse monoclonal acetylated a-tubulin was purchased
from Zymed laboratories, Invitrogen (catalog #: 32-2700). Different
combinations of secondary antibodies listed below were used for
immunofluorescence experiments: goat anti-mouse fluorescein iso-
thiocyanate (FITC) (catalog #: 81-6511, Zymed laboratories), donkey
anti-rabbit Texas Red (catalog #: ab6800, Abcam), and anti-mouse
Alexa 594, anti-rabbit FITC, donkey anti-goat IgG-TR (sc-2783),
donkey anti-rabbit IgG-FITC (sc-2090), donkey anti-goat Dylight 488
AbD Serotec (STAR 88D488), rabbit anti-mouse Alexa 488, goat
anti-mouse Fluor 594 (catalog #: A-11059 and A-10032, Molecular
Probes, Invitrogen).
Sequences of RNA interference (RNAi) duplex (Invitrogen)
For BBS6, sequences were 50–30-duplex 1: CCCUGUGUUGCUAAC
UGGCCAGAUU (catalog #: HSS112040); duplex 2: CCAGCAACCU
GACCUUGGACUGUUU (catalog #: HSS112041).
For BBS10, sequences were 50–30-duplex 1: CCUGGGAUUUAAU
AAGUCUGCAAAU; (catalog #: HSS128770); duplex 2: GGUCUCA
AAGAUGUUGCCGCCUCUCAAA; (catalog #: HSS128771).
For BBS12, sequences were 50–30-duplex 1: ACGCUGACAUGUU
UGUCUUUGGAAA; (catalog #: HSS136499); duplex 2: CCAUUGA
CAUGGUAAUCACUGUUAA; (catalog #: HSS136500).
Negative Universal Control Stealth RNAi with medium- and
low-GC content were used as controls (catalog #: 45-2001 and
45-2002, respectively). The p53 validated stealth RNAi was obtained
from Invitrogen (duplex:1 46-1492 and duplex 2: 46-1493).
Generation of BBS knockdown renal cells
BBS6, BBS10, and BBS12 transient-specific knockdown were achieved
using Stealth RNAi. The cells were cultured to 90% confluence and
Lipofectamine 2000 (Invitrogen) was used to deliver the small
interfering RNAs. Each duplex was individually transfected three
times. Transfection efficiency was assessed with the Block-iT Alexa
Fluor Red Fluoresecent Oligo (catalog #:14750-100, Invitrogen).
In parallel, cells were transfected with Stealth RNAi Negative Control
duplexes (catalog #: 12935-100, Invitrogen). The appropriate negative
control RNAi for each duplex was chosen based on the similarity in
the percentage of guanine/cytosine (GC) between the control small
interfering RNA and the BBS small interfering RNA. HCD cells were
transfected with either the BBS10 short hairpin RNA plasmid (h) or
the control short hairpin RNA plasmid-A (catalog #: sc-72620-SH or
sc-108060, respectively, Santa Cruz Biotechnology) using Lipofecta-
mine 2000 (catalog #: 11668-019) according to the manufacturer’s
protocol. After 24h, selection medium consisting of HCD culture
medium supplemented with 0.5mg/ml puromycin (catalog #: P7255;
Sigma-Aldrich) was cultured with constant puromycin selection
throughout all experiments.
Growth curve and metabolic assessment
The cells were cultured and harvested at different time points by
trypsin treatment. After trypsin inactivation and resuspension in
warm medium, cell number was determined using the Scepter
Handheld automated Cell Counter (catalog #:PHCC00000 from
Millipore) with the associated 60 mM Scepter tips (catalog #:
PHCC60050 from Millipore).
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Cell cycle analysis
HK-2 cells were cultured to 40% confluence. The cells were transfected
as indicated and cultured for 48 h before analysis. Human dermal
fibroblasts were cultured to 40% confluence and directly analyzed. The
cells were trypsinized and resuspended in culture medium. They were
then centrifuged for 5min at 1000 r.p.m., resuspended in ice-cold
phosphate buffered saline (PBS), and centrifuged again for 5min at
1000 r.p.m. The cells were finally resuspended in cold PBS, and cold
95% ethanol was added dropwise while mixing gently to a final
ethanol concentration of 70%. The cells were centrifuged and
resuspended in PBS twice before finally being resuspended in PBS
containing 50mg/ml RNAse and 15mg/ml propidium iodide (catalog
#: 70335, Fluka, Sigma-Aldrich, Lyon, France). The cells were
incubated overnight and were analyzed using a FACSCalibur flow
cytometer (BD Biosciences, le Pont de Claux, France).
cAMP enzyme-linked immunosorbent assay
The different treated HCD cells were cultured on Millicell inserts
in six-well plates to reach ciliated status. After the indicated treat-
ment, the cells were processed as indicated by the manufacturer’s
enzyme-linked immunosorbent assay protocol, and measured using
the cAMP Direct Immunoassay kit, Colorimetric (catalog #: 116811,
Calbiochem, Merck, Lyon, France).
Water absorption experiment
The experimental setup is depicted in the Supplementary Figure S9
online. The cells were cultured in Millicell Cell Culture Inserts in
six-well plates to full confluence, and full covering of the millicell
insert surface was verified by using the Millicell Electrical Resistance
System/Volt-Ohm Meter Millicell-ERS-2 (catalog #: MERS00002;
Millipore). At full confluence, the HCD monolayers showed a
transepithelial resistance of4500O cm2. To first validate that water
absorption was mediated by aquaporins after AVP treatment, we
performed a series of experiment with or without 300 mmol/l
mercury dichloride (catalog #: 21,546-5, Sigma-Aldrich) in presence
of an increasing osmotic pressure from apical to basolateral
compartments. To establish the osmotic gradient across the cell
monolayer, inside the well corresponding to the basolateral area
of the epithelial cells, culture medium was added containing
300mmol/l D-Mannitol (catalog #: S3889, Sigma-Aldrich). Water
transport was subsequently determined by measuring the apical
and basolateral medium weights with a precision balance after 2 h
incubation with apical AVP. Once the aquaporin-mediated water
absorption was validated, we used the dye-dilution approach to
monitor over time the water transport across the renal cells.
Briefly, after production of an osmotic gradient as described
above, 2ml of culture medium containing 0.25mg/ml of Dextran,
Texas Red 10,000, MW neutral dye was added inside the insert
corresponding to the luminal side. The cells were left to equilibrate
for 15min, followed by the luminal addition of 108mol/l AVP,
and a 5 ml aliquot was taken at the indicated time points and diluted
in 995ml PBS. From this diluted solution, 200ml was used to
measure fluorescence in a 96-well plate on a Tecan Infinite 200
quad4 monochromator (Tecan, Lyon, France). The generated data
were then analyzed using the Tecan Magellan Data Analysis software
using as blank pure PBS.
Live-cell imaging
At 40% confluence, the cells were transfected with the plasmid
AVPR2-GFP using Lipofectamine 2000 according to the manufac-
turer’s protocol. After 24 h, selection with G418 (catalog #: G8168,
Sigma-Aldrich) at a concentration of 0.2mg/ml of medium was
started until enough GFP-positive cells were obtained in the culture
plate. The cells were then grown to reach ciliated status, and the
plasma membrane was then stained with Image-iT Live Plasma
Membrane and Nuclear labeling Kit (catalog #: I34406) according
to the manufacturer’s protocol. Pictures were acquired on a Zeiss
Axiovert coupled with a Zeiss MRM B/W camera (Lordil, Villers-les-
Nancy, France).
Statistics
Results are shown as means±s.d. Significance of the results
was determined by paired t-tests. A value of Po0.05 was consi-
dered to denote statistical significance and was marked with an
asterisk.
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